Skip to main content
PMC home page
Clinical and Translational Allergy logoLink to Clinical and Translational Allergy
. 2021 Oct 12;11(8):e12069. doi: 10.1002/clt2.12069

Gram‐negative microbiota is related to acute exacerbation in children with asthma

Yoon Hee Kim 1,2, Haerin Jang 2,3, Soo Yeon Kim 2,3, Jae Hwa Jung 2,3, Ga Eun Kim 2,3, Mi Reu Park 2,3, Jung Yeon Hong 4, Mi Na Kim 2,3, Eun Gyul Kim 2,3, Min Jung Kim 2,5, Kyung Won Kim 2,3, Myung Hyun Sohn 2,3,✉
PMCID: PMC8507365  PMID: 34667591

Abstract

Background

The upper‐airway microbiota may be associated with the pathogenesis of asthma and useful for predicting acute exacerbation. However, the relationship between the lower‐airway microbiota and acute exacerbation in children with asthma is not well understood. We evaluated the characteristics of the airway microbiome using induced sputum from children with asthma exacerbation and compared the microbiota‐related differences of inflammatory cytokines with those in children with asthma.

Methods

We analysed the microbiome using induced sputum during acute exacerbation of asthma in children. We identified microbial candidates that were prominent in children with asthma exacerbation and compared them with those in children with stable asthma using various analytical methods. The microbial candidates were analysed to determine their association with inflammatory cytokines. We also developed a predictive functional profile using PICRUSt.

Results

A total of 95 children with allergic sensitisation including 22 with asthma exacerbation, 67 with stable asthma, and 6 controls were evaluated. We selected 26 microbial candidates whose abundances were significantly increased, decreased, or correlated during acute exacerbation in children with asthma. Among the microbial candidates, Campylobacter, Capnocytophaga, Haemophilus, and Porphyromonas were associated with inflammatory cytokines including macrophage inflammatory protein (MIP)‐1β, programmed death‐ligand 1, and granzyme B. Both Campylobacter and MIP‐1β levels were correlated with sputum eosinophils. Increased lipopolysaccharide biosynthesis and decreased glycan degradation were observed in children with asthma exacerbation.

Conclusion

Gram‐negative microbes in the lower airway were related to acute exacerbation in children with asthma. These microbes and associated cytokines may play a role in exacerbating asthma in children.

Keywords: asthma, children, induced sputum, lipopolysaccharide, microbiome

1. INTRODUCTION

Acute exacerbation of asthma in children is remains difficult to treat and can result in severe morbidity including deteriorated lung function and mortality. 1 Viral respiratory infections are considered as main triggering factor in children with asthma exacerbation and may be influenced by risk factors such as allergen sensitisation and exposure, antiviral immunity, and genetic predisposition. 2 , 3 Numerous studies of the airway microbiome using culture‐independent next‐generation sequencing methods for isolating microbes have suggested that host factors are related to asthma exacerbation. 4

Although which respiratory sample is the most appropriate for microbiome analysis is currently unclear, nasal samples are generally evaluated in children with asthma to predict acute exacerbation because they are easy to collect, particularly from children. Many studies of the respiratory microbiome have indicated that using nasal samples is useful for predicting biomarkers in children with asthma exacerbation. 5 , 6 However, nasal samples mainly reflect the upper airway, and induced sputum samples may be superior to nasal or oral samples for assessing the bronchial microbiota composition. 7 As asthma exacerbation may develop from an exaggerated lower airway response to an environmental stimulus and acute severe lower airway inflammation, respiratory microbiome analysis using induced sputum could be useful for understanding the pathophysiology of asthma exacerbation. 8

In this study, we evaluated the characteristics of the airway microbiome using induced sputum in children with asthma exacerbation. In addition, by comparing inflammatory cytokines with distinct microbiota in acute exacerbation, we predicted the role of the airway microbiota in children with asthma exacerbation.

2. METHODS

2.1. Subjects

We enrolled children who visited the Severance Children's Hospital for work‐up or treatment of asthma or routine health check‐up from December 2012 to September 2018.

We defined three groups of patients: asthma exacerbation, stable asthma, and respiratory heathy control groups. Asthma was diagnosed based on current episodic respiratory symptoms such as recurrent cough or dyspnoea, shortness of breath, chest tightness, and airway hyperresponsiveness or bronchodilator response according to the guidelines of the American Thoracic Society. 9 Stable asthma was defined as no asthmatic exacerbation during the preceding 4 weeks accompanied by the need for systemic corticosteroids or an increased use of inhaled corticosteroids, the use of rescue treatment ≤3 times per week, and no clinical indication for a change in medication. Asthma exacerbation was defined as the worsening of asthma requiring the use of systemic corticosteroids or hospitalisation to prevent a serious outcome. 10 Respiratory healthy controls had normal lung function without airway hyperresponsiveness and had never had a doctor's diagnosis of asthma.

The stable asthma and healthy control groups were enrolled in an outpatient clinic and underwent spirometry, sputum induction, and blood sampling at the first visit followed by provocholine challenge test at the second visit. The asthma exacerbation group was admitted to the hospital because of worsening of asthma symptoms and underwent spirometry, sputum induction, blood sampling, and nasopharyngeal swab within 24 h after hospitalisation. The nasopharyngeal swabbed samples were analysed for 12 common respiratory viruses with a multiplex PCR/RT‐PCT kit (SolGent, Daejeon, Korea). 11 These viruses included human rhinovirus, respiratory syncytial virus, human bocavirus, influenza A and B virus, human metapneumovirus, adenovirus, human coronaviruses 229E, OC43, and parainfluenza viruses 1–3.

In the blood samples, total serum IgE and specific IgE levels were measured by the Pharmacia CAP assay (Uppsala, Sweden). A specific IgE test was performed for common allergens in Korea, including 2 types of dust mites such as Dermatophagoides pteronyssinus and Dermatophagoides farina, cat and dog epithelium, and cockroach, as well as mould and pollen allergens, including Alternaria, birch, mugwort, Japanese hop, and ragweed. Atopy was defined as ≥0.35 KUa/L specific IgE to more than one allergen.

Sputum induction and processing methods are described in detail in the Supplementary Methods. For the fidelity of the induced sputum collected, the proportion of squamous cells was checked and the samples were considered acceptable for analysis when the squamous cell proportion was <20% of the total cells. 12 For microbiome analysis, the DNA extraction, PCR amplification and sequencing, and bioinformatics analysis procedures are also described in the Supplementary Methods.

This study was approved by the Institutional Review Board of Severance Hospital (protocol no. 4‐2004‐0036). Written informed consent was obtained from the participants and their parents.

2.2. Evaluating the microbial candidates as biomarkers of asthma exacerbation

For biomarker discovery in children with asthma exacerbation, we used three different types of data analysis methods including the linear discriminant analysis effect size (LEfSe) method, 13 similarity of percentages (SIMPER) analysis, 14 and microbiota network analysis using SparCC. 15 In using LEfSe analysis, we defined the microbial candidates as those showing significant LEfSe values in children with asthma exacerbation compared to those in both children with stable asthma and controls. SIMPER analysis was performed to define the microbial candidates that could explain the difference in microbiome composition between children with asthma exacerbation and those with stable asthma with up to 80% dissimilarity. Microbiota network analysis was performed using a correlation coefficient of r > 0.25 or r < −0.25 and p value < 0.01, and the results were visualised with Cytoscape (version 3.4.0) software for children with asthma exacerbation. We identified the microbial candidates showing significant correlations with each other.

Based on the functional profiles predicted by the PICRUSt 16 and MinPath algorithms, 17 functional biomarkers were identified by LEfSe analysis among the three groups. All analytical methods were performed in EzBioCloud 16S‐based MTP, the ChunLab's bioinformatics cloud platform.

2.3. Cytokine analysis

Cytokine analysis of sputum was performed in children with asthma exacerbation and stable asthma. A human fixed immunotherapy discovery magnetic panel‐24 plex kit (Magnetic Luminex® Performance Assay multiplex kit, R&D Systems, Minneapolis, MN, USA) was used for cytokine analysis. This kit was used to analyse the cluster of differentiation 40, granulocyte–macrophage colony‐stimulating factor, granzyme B, interferon‐α, interferon‐γ, interleukin (IL)‐1α, IL‐1β, IL‐1Ra, IL‐2, IL‐4, IL‐6, IL‐8, IL‐10, IL‐12p70, IL‐13, IL‐15, IL‐17A, IL‐33, C‐X‐C motif chemokine 10, monocyte chemoattractant protein‐1, macrophage inflammatory proteins (MIP)‐1α, MIP‐1β, programmed death‐ligand (PD‐L) 1, and tumour necrosis factor‐α.

2.4. Statistical analysis

Subjects' characteristics were compared among children with asthma exacerbation, those with stable asthma, and controls using Kruskal–Wallis test and pairwise comparison. To assess the relationship between the microbial candidates and the significant inflammatory cytokines in children with asthma exacerbation, Spearman's rank correlation was used. Correction for multiple comparisons was carried out using the Benjamini–Hochberg false discovery rate method. To display the results graphically, we plotted a correlation matrix showing the relationships between the microbial candidates and the significant inflammatory cytokines in children with asthma exacerbation. All p‐values < 0.05 were considered as statistically significant. SPSS version 23 statistical software (SPSS, Inc., Chicago, IL, USA) and R statistical package (R version 3.2.5.; Institute for Statistics and Mathematics, Vienna, Austria; www.R‐project.org) were used.

3. RESULTS

3.1. Clinical characteristics

A total of 127 children including 22 children with asthma exacerbation, 83 with stable asthma, and 22 controls were enrolled. All children with asthma exacerbation showed atopy. Because atopy in asthma has been suggested to strongly influence the human microbiome, 18 , 19 we excluded children without atopy. A total of 95 children with allergic sensitisation including 22 with asthma exacerbation, 67 with stable asthma, and 6 controls were evaluated.

The subjects’ clinical characteristics are shown in Table 1. The median ages of children with asthma exacerbation and stable asthma were 9.0 and 8.0 years, percentages of males were 68.2% and 74.6%, and median total IgE levels were 484 and 439 IU/ml, respectively. In children with asthma exacerbation, the blood and sputum eosinophil were 460/mm2 and 3.0%. Among the 22 children with asthma exacerbation, 13 had rhinovirus infection and 1 had influenza virus infection according to multiplex PCR analysis of nasopharyngeal swab samples. The spirometric indices were lower in children with asthma exacerbation than in those with stable asthma and controls.

TABLE 1.

Subjects' characteristics (N = 95)

Asthma exacerbation (N = 22) Stable asthma (N = 67) Control (N = 6)
Age, years 9.0 (6.4/10.9)* 8.0 (6.6/9.7)* 13.2 (10.7/14.9)
Male sex, n (%) 15 (68.2) 50 (74.6) 4 (66.7)
Total IgE, IU/ml 484 (230/973) 439 (201/919) 448 (110/1065)
Blood eosinophil 460 (208/663) 420 (290/710) 220 (180/430)
Sputum eosinophil, % 3.0 (0.0/21.5) 2.0 (0.0/10.0) 2.0 (0.0/4.8)
Infected pathogen
Rhinovirus 13 (59.1)
Influenza 1 (4.5)
Pulmonary function
FEV1, % predicted 72.6 ± 21.4*,** 95.6 ± 15.9 110.4 ± 8.4
Δ FEV1, % 4.6 (2.0/19.6) 7.5 (4.0/13.3)* 1.6 (−0.2/3.6)
FEV1/FVC 77.4 (65.7/82.8)*,** 81.4 (73.5/85.4) 90.3 (86.8/92.2)
Open in a new tab

Note: All subjects are atopic.

Abbreviations: FEV1, forced expiratory volume in one second; FVC, forced vital capacity.

* p < 0.05 versus healthy control.

** p < 0.05 versus stable asthma.

3.2. Taxon distribution and α, β‐diversity

The taxa composition was visualised as stacked bar graphs at the phylum and genus levels, as shown in Figures S1 and S2. At the phylum level, Proteobacteria was more abundant and Saccharibacteria_TM7 and Actinobacteria were less abundant in children with asthma exacerbation. At the genus level, Veillonella, Neisseria, Haemophilus, Fusobacterium, Oribacterium, Campylobacter, and Capnocytophaga showed higher abundance and Saccharimonas, Rothia, Porphyromonas, Gemella, and Actinomyces showed lower abundance in this group.

The α‐diversity indices about species richness including ACE, Chao 1, and Jackknife and species diversity including NPShannon, Shannon, Simpson, and phylogenetic diversity did not differ between children with asthma exacerbation and those with stable asthma (Table S1). The β‐diversity indices including Jensen‐Shannon, Bray‐Curtis, Generalised UniFrac, and UniFrac significantly differed between children with asthma exacerbation and those with stable asthma (Table S2).

3.3. Microbial candidates in asthma exacerbation

As the β‐diversity indices between children with asthma exacerbation and those with stable asthma were significantly different, we identified the prominently increased or decreased the microbial candidates in children with asthma exacerbation compared to in those with stable asthma by LEfSe and SIMPER analysis.

LEfSe analysis showed that Capnocytophaga was the only prominently increased the microbial candidate in children with asthma exacerbation compared to in those with stable asthma and controls, whereas the prominently decreased the microbial candidates in those with asthma exacerbation were Saccharimonas, Rothia, Gemella, Bulleidia, and Eubacterium_g10 (Figure 1).

FIGURE 1.

FIGURE 1

Open in a new tab

Heatmap plotted from linear discriminant analysis effect size (LEfSe) analysis at the genus level between groups. Capnocytophaga was increased in children with asthma exacerbation compared to in those with stable asthma and controls, whereas Saccharominas, Rothia, Gemella, Bulleidia, and Eubacterium_g10 were decreased

According to SIMPER analysis, the microbial candidates that could explain the 80% dissimilarity in microbiome composition between those with asthma exacerbation and those with stable asthma were Streptococcus, Neisseria, Veillonella, Haemophilus, Prevotella, Granulicatella, Ralstonia, Actinomyces, Rothia, Saccharimonas, Fusobacterium, Selemonas, Gemella, Porphyromonas, Capnocytophaga, Peptostreptococcus, Leptotrichia, Lautrophia, and Oribacterium (Figure 2).

FIGURE 2.

FIGURE 2

Open in a new tab

Relative abundance (operational taxonomic unit abundance) of discriminant microbiota plotted from SIMPER analysis at the genus level between groups. The 19 microbial candidates listed in the heatmap explained the difference between asthma exacerbation and stable asthma with up to 80% cumulative dissimilarity (Dis.)

To clarify the association among the microbes during acute exacerbation, a microbiota network was generated in children with asthma exacerbation (Figure 3). Significantly correlated the microbial candidates included Campylobacter, Haemophilus, Neisseria, Granulicatella, Peptostreptococcus, Fusobacterium, and Streptococcus, among others.

FIGURE 3.

FIGURE 3

Open in a new tab

Network analysis of microbiota in asthma exacerbation. Node size is proportional to the mean relative abundance. Node colour (red represents increased microbiota and grey represents decreased microbiota in asthma exacerbation) and node hue is proportional to the difference in microbiota relative abundance between asthma exacerbation and stable asthma. Each edge: a significant correlation coloured to indicate either positivity (red) or negativity (grey). Edge width and transparency are proportional to the absolute value of the correlation coefficient. Correlations were determined with SparCC with a correlation cut‐off R value of greater than 0.25 or less than −0.25

Finally, we selected the 26 microbial candidates significantly increased, decreased, or correlated with each other during acute exacerbation of asthma in children through LEfSE, SIMPER, and network analysis.

3.4. Relationship between microbial candidates and significant cytokines

The significantly increased inflammatory cytokines in children with asthma exacerbation compared as those with stable asthma were granzyme B, IL‐2, IL‐10, IL‐17A, MIP‐1α, MIP‐1β, PD‐L1, and tumour necrosis factor‐α, as shown in Table S3. Because the airway microbiome and inflammatory cytokines in asthma have been shown to be closely related, 20 we analysed the correlation between these inflammatory cytokines and the 26 microbial candidates in children with asthma shown, as shown in Figure 4. Campylobacter was positively correlated with granzyme B, MIP‐1β, and PD‐L1. Capnocytophaga was positively correlated with MIP‐1β, and Haemophilus was positively correlated with PD‐L1. Peptostreptococcus and Porphyromonas were negatively correlated with PD‐L1.

FIGURE 4.

FIGURE 4

Open in a new tab

Correlation between microbial candidates distinct in asthma exacerbation from LEfSe, SIMPER, and network analysis using SparCC and prominently increased inflammatory cytokines in asthma exacerbation. Node size is proportional to Spearman's rank correlation coefficient. Red bar: positive correlation; blue bar: negative correlation; dark coloured node: false discovery rate (FDR) p < 0.05; light coloured node: FDR p ≥ 0.05

As MIP‐1β has been known to play a role in eosinophilic recruitment, 21 we analysed the correlation among levels of MIP‐1β and sputum eosinophil counts (Spearman coefficient r = 0.478, p = 0.028) in children with asthma exacerbation. Campylobacter and Capnocytophaga, which were significantly correlated with MIP‐1β in this study, showed similar results in correlation analysis with sputum eosinophil counts; only Campylobacter showed a significant correlation with sputum eosinophils (Spearman coefficient r = 0.462, p = 0.035).

3.5. Prediction of metagenome function in asthma exacerbation

The predicted function of the airway microbiome was assessed to determine whether it was differed between children with asthma exacerbation and children with stable asthma and controls using PICRUSt, as shown in Figure 5. Lipopolysaccharide (LPS) biosynthesis was increased, whereas glycan degradation was decreased in children with asthma exacerbation compared to in those with stable asthma and control.

FIGURE 5.

FIGURE 5

Open in a new tab

Heatmap plotted from linear discriminant analysis effect size analysis of predicted functional profiles using PICRUSt between groups. Lipopolysaccharide biosynthesis was increased and glycan degradation was decreased in children with asthma exacerbation compared to in children with stable asthma and controls

4. DISCUSSION

During acute exacerbation of allergic asthma in children, gram‐negative microbes were increased prominently, showing a relationship with increased granzyme B, MIP‐1β, and PD‐L1 in induced sputum. Among the increased gram‐negative microbes, Campylobacter was associated with increased MIP‐1β and the sputum eosinophils, indicating that it plays a role in asthma exacerbation in children. Predictive metagenome functional analysis showed increased LPS biosynthesis and decreased glycan degradation in children with asthma exacerbation.

Campylobacter was increased significantly according to LEfSe analysis and showed a significant correlation with several inflammatory cytokines including granzyme B, MIP‐1β, and PD‐L1, which were increased in asthma exacerbation. Although Campylobacter is typically considered as a gastrointestinal pathogen, it can be increased in lung in chronic obstructive pulmonary disease and interstitial lung disease. 22 , 23 This finding can be explained by the fact that gastroesophageal reflux or oral aspiration may contribute to exacerbation of chronic lung disease. 24 In the gut–lung axis, gut microbes may influence the lungs via the spilling over of increased gut microbes and their inflammatory mediators in the body. 25 Although Campylobacter has not been widely studied in asthma, it may play a role in asthma exacerbation as a driving microbe, as it showed a close correlation with other microbes in bacterial network analysis.

MIP‐1β was recently reported to recruit eosinophils into the airway and was found to be increased in asthma exacerbation in an eosinophil‐dominant biological cluster. 21 , 26 Campylobacter can induce eosinophil chemotaxis as well as degranulation and release of eosinophil cationic proteins and major basic proteins. 27 Since Campylobacter was correlated with both MIP‐1β and eosinophils in our study; we hypothesised that MIP‐1β mediated the relationship between Campylobacter and eosinophils. Eosinophil inflammation is exaggerated upon exposure to allergens, and allergic asthma showing allergen sensitisation is more important in children compared to other asthma phenotypes including neutrophil‐ or obesity‐related asthma. 28 Therefore, the identification of Campylobacter provides a new perspective in children with allergic asthma exacerbation.

Granzyme B signalling was reported to be induced by Campylobacter infection in humans, which may be related to the inflammatory response. 29 Granzyme B was suggested as a novel target molecule in allergic pulmonary inflammation 30 and was reported to be increased in fatal asthma, as it was delivered into target cells to exert its cytotoxic function and it cleaved extracellular matrix components, contributing to remodelling in chronic inflammation. 31 Considering these reports, the relationship between increased granzyme B and Campylobacter in our subjects may play a role during asthma exacerbation.

PD‐L1 was shown to be correlated with most of the microbial candidates in our study. PD‐L1 has been reported to be an important target molecule in cancer therapy, and the gut microbiome can affect anti‐PD‐L1 treatment. 32 Although few studies have evaluated the relationship between PD‐L1 and asthma, PD‐L1 and PD‐L2 are known to affect asthma differently and PD‐L1 may strengthen Th2 inflammation and increase airway hyper‐responsiveness in asthma. 33 From the perspective of acute infection, PD‐L1 was reported to suppress CD8 T‐cell immunity, preventing the clearance of infected pathogens. 34 , 35 The dual roles of PD‐L1 in asthma, which are strengthening Th2 inflammation and weakening innate immunity from infected pathogens, can explain its contribution to asthma exacerbation.

Haemophilus was increased in children with asthma exacerbation compared to in those with stable asthma according to SIMPER analysis with 7% dissimilarity and showed a significant correlation with PD‐L1. This increase in Haemophilus is consistent with the findings of previous studies of severe asthma, which showed that Haemophilus suppressed host innate immunity and may contribute to the persistence of infection in allergic asthma. 36 , 37 , 38 Haemophilus was shown to be significantly correlated with other microbiotas during asthma exacerbation in bacterial network analysis, which was also found in another study of neutrophilic asthma. The most common causative factor of asthmas exacerbation is respiratory infection such as with mycoplasma and rhinovirus, for which the infective environment can be neutrophil dominant. 36

In contrast, Haemophilus species levels differ in infants and children with asthma according to age and are related to a reduced risk of exacerbation in children. 6 This discrepancy may have resulted from the use of different sampling time points. We collected samples during asthma exacerbation, whereas others studies performed regular sampling independently of asthma exacerbation. In addition, we collected induced sputum, whereas other studies used nasal swabbed samples, which may be resulted in differences between the results. Therefore, our data more accurately explains the pathophysiology of asthma exacerbation, whereas other studies predicted the development of asthma exacerbation. 7

Capnocytophaga and Porphyromonas showed a prominent change and were the microbial candidates involved in asthma exacerbation according to LEfSe and SIMPER analysis. However, these genera were present in low abundance and not related in the bacterial network. Therefore, their influence might be smaller than those of other candidate microbes, which is supported by previous studies. However, further studies of these microbes may improve the understanding of the mechanism of asthma exacerbation. The microbes were found in the upper airway or oral cavity, where respiratory infection related to asthma exacerbation can occur. 39 , 40

Although microbial functional analysis is helpful for understanding the interactions between microorganisms and host health, we did not perform metagenomic functional analysis because of its high cost and requirement for large amounts of DNA. 41 Therefore, we used the PICRUSt software program, which is designed to predict the metagenome functional content from marker genes using 16S rRNA surveys. 17 LPS was found to be increased, possibly because of increased levels of gram‐negative microbes during asthma exacerbation. A recent study reported that bacterial LPS binding enhanced virus stability and promoted viral infectivity in the gastrointestinal tract. 42 This finding should be further evaluated in the respiratory tract because respiratory viral infection is an important risk factor of asthma exacerbation. In our study, glycan degradation was decreased, reducing short‐chain fatty acids reduced. Short‐chain fatty acids are known to promote regulatory T lymphocytes, which can protect against asthma development. 43 , 44

There were some limitations to this study. First, we could not control systemic steroid uses for asthma exacerbation, which may have influenced the airway microbial composition. However, this limitation is inevitable in clinical research of asthma exacerbation. To minimise this effect, we collected induced sputum within 24 h of hospital visits. In addition, we could not evaluate the airway microbiome according to age. Considered that there was no difference in age between children with asthma exacerbation and those with stable asthma and that most children were more than 8 years old, an age at which the airway microbiome changes, this confounding effect may have been small in this study. 5

This is the first study to evaluate the airway microbiome using induced sputum, which can reflect the lower airway state in children with asthma. Sputum induction was performed at the beginning of asthma exacerbation, enabling accurate assessment of the airway inflammatory status in children with asthma exacerbation. As we identified important the microbial candidates through a multifaceted analysis including LEfSe, SIMPER, and bacterial network analysis, and identified cytokines related to these candidates by multiple correction, our results provide precise information for understating asthma exacerbation relating and its relationship with the airway microbiome in children.

In conclusion, gram‐negative microbes in the lower airway were related to the acute exacerbation state in children with asthma by increasing inflammatory cytokines such as granzyme B, MIP‐1β, and PD‐L1 and changing the metabolic status such as LPS biosynthesis and glycan degradation (Figure 6). These microbes and related cytokines and functional pathways may play a role in asthma exacerbation in children.

FIGURE 6.

FIGURE 6

Open in a new tab

Gram‐negative microbes in the lower airway that increase lipopolysaccharide biosynthesis and decrease glycan degradation may promote acute exacerbation of allergic asthma in children via inflammatory cytokines including programmed death‐ligand 1, macrophage inflammatory proteins (MIP)‐1β, and granzyme B. Among the increased gram‐negative microbes, Campylobacter was associated with increased MIP‐1β and sputum eosinophils, indicating that this genus plays a role in asthma exacerbation in children

CONFLICT OF INTEREST

All authors of this study declare that there is no conflict of interest.

Supporting information

Supporting Information S1

Click here for additional data file. (54.5KB, doc)

Figure S1

Click here for additional data file. (15.2KB, tiff)

Figure S2

Click here for additional data file. (26.3KB, tiff)

Table S1

Click here for additional data file. (15.8KB, docx)

Table S2

Click here for additional data file. (14.7KB, docx)

Table S3

Click here for additional data file. (17.6KB, docx)

ACKNOWLEDGMENTS

The authors would like to thank Dong‐Su Jang, MFA (Medical Illustrator), for his help with the illustrations and Hye Sun Lee, PhD (Medical Research Support Section, Department of Biostatistics, Yonsei University College of Medicine), for her assistance with the statistics. This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (grant number 2018R1D1A1B07040398, 2018R1A5A2025079 and 2020R1A2B5B02001713); Faculty Research Grant of Yonsei University College of Medicine (6‐2016‐0106).

Kim YH, Jang H, Kim SY, et al. Gram‐negative microbiota is related to acute exacerbation in children with asthma. Clin Transl Allergy. 2021;e12069. doi:10.1002/clt2.12069

REFERENCES

  • 1. Papi A, Brightling C, Pedersen SE, Reddel HK. Asthma. Lancet. 2018;391(10122):783‐800. [DOI] [PubMed] [Google Scholar]
  • 2. Castillo JR, Peters SP, Busse WW. Asthma exacerbations: pathogenesis, prevention, and treatment. J Allergy Clin Immunol Pract. 2017;5(4):918‐927. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3. Cook J, Saglani S. Pathogenesis and prevention strategies of severe asthma exacerbations in children. Curr Opin Pulm Med. 2016;22(1):25‐31. [DOI] [PubMed] [Google Scholar]
  • 4. Huang YJ, Boushey HA. The microbiome in asthma. J Allergy Clin Immunol. 2015;135(1):25‐30. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5. Zhou Y, Jackson D, Bacharier LB, et al. The upper‐airway microbiota and loss of asthma control among asthmatic children. Nat Commun. 2019;10(1):5714. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6. McCauley K, Durack J, Valladares R, et al. Distinct nasal airway bacterial microbiotas differentially relate to exacerbation in pediatric patients with asthma. J Allergy Clin Immunol. 2019;144(5):1187‐1197. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7. Durack J, Huang YJ, Nariya S, et al. Bacterial biogeography of adult airways in atopic asthma. Microbiome. 2018;6(1):104. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8. Wark PA, Gibson PG. Asthma exacerbations. 3: pathogenesis. Thorax. 2006;61(10):909‐915. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am J Respir Crit Care Med. 2005;171(8):912‐930. [DOI] [PubMed] [Google Scholar]
  • 10. Fergeson JE, Patel SS, Lockey RF. Acute asthma, prognosis, and treatment. J Allergy Clin Immunol. 2017;139(2):438‐447. [DOI] [PubMed] [Google Scholar]
  • 11. Chun JK, Lee JH, Kim HS, et al. Establishing a surveillance network for severe lower respiratory tract infections in Korean infants and young children. Eur J Clin Microbiol Infect Dis. 2009;28(7):841‐844. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12. Efthimiadis A, Spanevello A, Hamid Q, et al. Methods of sputum processing for cell counts, immunocytochemistry and in situ hybridisation. Eur Respir J Suppl. 2002;37:19s‐23s. [DOI] [PubMed] [Google Scholar]
  • 13. Segata N, Izard J, Waldron L, et al. Metagenomic biomarker discovery and explanation. Genome Biol 2011;12(6).R60. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14. Wickham H. ggplot2: Elegant Graphics for Data Analysis. Springer; 2016. [Google Scholar]
  • 15. Friedman J, Alm EJ. Inferring correlation networks from genomic survey data. PLoS Comput Biol. 2012;8(9).e1002687. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16. Ye Y, Doak TG. A parsimony approach to biological pathway reconstruction/inference for genomes and metagenomes. PLoS Comput Biol. 2009;5(8):e1000465. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17. Langille MG, Zaneveld J, Caporaso JG, et al. Predictive functional profiling of microbial communities using 16S rRNA marker gene sequences. Nat Biotechnol. 2013;31(9):814‐821. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18. Marsland BJ, Salami O. Microbiome influences on allergy in mice and humans. Curr Opin Immunol. 2015;36:94‐100. [DOI] [PubMed] [Google Scholar]
  • 19. Durack J, Lynch SV, Nariya S, et al. Features of the bronchial bacterial microbiome associated with atopy, asthma, and responsiveness to inhaled corticosteroid treatment. J Allergy Clin Immunol. 2017;140(1):63‐75. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20. Sullivan A, Hunt E, MacSharry J, Murphy DM. The microbiome and the pathophysiology of asthma. Respir Res. 2016;17(1):163. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21. Kobayashi Y, Konno Y, Kanda A, et al. Critical role of CCL4 in eosinophil recruitment into the airway. Clin Exp Allergy. 2019;49(6):853‐860. [DOI] [PubMed] [Google Scholar]
  • 22. Pragman AA, Kim HB, Reilly CS, Wendt C, Isaacson RE. The lung microbiome in moderate and severe chronic obstructive pulmonary disease. PLoS One. 2012;7(10).e47305. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23. Salisbury ML, Han MK, Dickson RP, Molyneaux PL. Microbiome in interstitial lung disease: from pathogenesis to treatment target. Curr Opin Pulm Med. 2017;23(5):404‐410. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24. Lee JS, Ryu JH, Elicker BM, et al. Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;184(12):1390‐1394. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25. Wypych TP, Wickramasinghe LC, Marsland BJ. The influence of the microbiome on respiratory health. Nat Immunol. 2019;20(10):1279‐1290. [DOI] [PubMed] [Google Scholar]
  • 26. Ghebre MA, Pang PH, Diver S, et al. Biological exacerbation clusters demonstrate asthma and chronic obstructive pulmonary disease overlap with distinct mediator and microbiome profiles. J Allergy Clin Immunol. 2018;141(6):2027‐2036.e12. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27. Hogan SP, Waddell A, Fulkerson PC. Eosinophils in infection and intestinal immunity. Curr Opin Gastroenterol. 2013;29(1):7‐14. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28. Just J, Bourgoin‐Heck M, Amat F. Clinical phenotypes in asthma during childhood. Clin Exp Allergy. 2017;47(7):848‐855. [DOI] [PubMed] [Google Scholar]
  • 29. Ayllón N, Jiménez‐Marín Á, Argüello H, et al. Comparative proteomics reveals differences in host‐pathogen interaction between infectious and commensal relationship with Campylobacter jejuni. Front Cell Infect Microbiol. 2017;7:145. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30. Farhadi N, Lambert L, Triulzi C, Openshaw PJ, Guerra N, Culley FJ. Natural killer cell NKG2D and granzyme B are critical for allergic pulmonary inflammation. J Allergy Clin Immunol. 2014;133(3):827‐835.e3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31. Annoni R, Silva LF, Nussbaumer‐Ochsner Y, et al. Increased expression of granzymes A and B in fatal asthma. Eur Respir J. 2015;45(5):1485‐1488. [DOI] [PubMed] [Google Scholar]
  • 32. Zou W, Wolchok JD, Chen L. PD‐L1 (B7‐H1) and PD‐1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations. Sci Transl Med. 2016;8(328).328rv4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33. Singh AK, Stock P, Akbari O. Role of PD‐L1 and PD‐L2 in allergic diseases and asthma. Allergy. 2011;66(2):155‐162. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34. Telcian AG, Laza‐Stanca V, Edwards MR, et al. RSV‐induced bronchial epithelial cell PD‐L1 expression inhibits CD8+ T cell nonspecific antiviral activity. J Infect Dis. 2011;203(1):85‐94. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35. Zdrenghea MT, Johnston SL. Role of PD‐L1/PD‐1 in the immune response to respiratory viral infections. Microbes Infect. 2012;14(6):495‐499. [DOI] [PubMed] [Google Scholar]
  • 36. Taylor SL, Leong LEX, Choo JM, et al. Inflammatory phenotypes in patients with severe asthma are associated with distinct airway microbiology. J Allergy Clin Immunol. 2018;141(1):94‐103.e15. [DOI] [PubMed] [Google Scholar]
  • 37. Simpson JL, Daly J, Baines KJ, et al. Airway dysbiosis: Haemophilus influenzae and Tropheryma in poorly controlled asthma. Eur Respir J. 2016;47(3):792‐800. [DOI] [PubMed] [Google Scholar]
  • 38. Essilfie AT, Simpson JL, Dunkley ML, et al. Combined Haemophilus influenzae respiratory infection and allergic airways disease drives chronic infection and features of neutrophilic asthma. Thorax. 2012;67(7):588‐599. [DOI] [PubMed] [Google Scholar]
  • 39. Brook I. Chronic sinusitis in children and adults: role of bacteria and antimicrobial management. Curr Allergy Asthma Rep. 2005;5(6):482‐490. [DOI] [PubMed] [Google Scholar]
  • 40. Card JW, Carey MA, Voltz JW, et al. Modulation of allergic airway inflammation by the oral pathogen Porphyromonas gingivalis. Infect Immun. 2010;78(6):2488‐2496. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41. Heintz‐Buschart A, Wilmes P. Human gut microbiome: function matters. Trends Microbiol 2018;26(7):563‐574. [DOI] [PubMed] [Google Scholar]
  • 42. Robinson CM, Jesudhasan PR, Pfeiffer JK. Bacterial lipopolysaccharide binding enhances virion stability and promotes environmental fitness of an enteric virus. Cell Host Microbe. 2014;15(1):36‐46. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43. Koropatkin NM, Cameron EA, Martens EC. How glycan metabolism shapes the human gut microbiota. Nat Rev Microbiol. 2012;10(5):323‐335. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44. Gray LE, O'Hely M, Ranganathan S, Sly PD, Vuillermin P. The maternal diet, gut bacteria, and bacterial metabolites during pregnancy influence offspring asthma. Front Immunol. 2017;8:365. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supporting Information S1

Click here for additional data file. (54.5KB, doc)

Figure S1

Click here for additional data file. (15.2KB, tiff)

Figure S2

Click here for additional data file. (26.3KB, tiff)

Table S1

Click here for additional data file. (15.8KB, docx)

Table S2

Click here for additional data file. (14.7KB, docx)

Table S3

Click here for additional data file. (17.6KB, docx)

Articles from Clinical and Translational Allergy are provided here courtesy of Wiley

RESOURCES